| SpectRx, Inc. | |||
| Ticker: | SPRX | 6025A Unity Drive | |
| Exchange: | NASDAQ-National Market | Norcross, GA 30071 | |
| Industry: | Manufacturing (SIC Code 3845) | (770) 242-8723 | |
| Type of Shares: | Common Shares | Filing Date: | 2/27/97 | |
| U.S. Shares: | 2,201,699 | Offer Date: | 6/30/97 | |
| Non-U.S. Shares: | 0 | Filing Range: | $10.00 - $12.00 | |
| Primary Shares: | 2,000,000 | Offer Price: | $7.00 | |
| Secondary Shares: | 201,699 | Gross Spread: | $0.49 | |
| Offering Amount: | $24,218,689 | Selling: | $0.27 | |
| Expenses: | $650,000 | Reallowance: | $0.10 | |
| Shares Out After: | 7,567,590 |
| Manager | Tier | Phone |
| Hambrecht & Quist Incorporated | Lead Manager | (415) 439-3626 |
| Volpe, Welty & Company | Co-manager | (415) 274-4463 |
| Issuer's Law Firm: | Wilson, Sonsini, Goodrich & Rosati |
| Bank's Law Firm: | White & Case |
| Auditor: | Arthur Andersen |
| Registrar/Transfer Agent: | SunTrust Bank of Atlanta |
Dollar amounts in U.S. millions except for per share data | |||||
| Full Year Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/96 | 12/31/96 | ||||
| Revenue: | $0.45 | Assets: | $5.95 | ||
| Net Income: | -$3.18 | Curr Assets: | |||
| EPS: | -$1.03 | Liabilities: | $1.19 | ||
| Prior EPS: | Curr Liabilities: | ||||
| Cash Flow/Oper: | -$2.45 | Equity: | $4.75 | ||
| Cash Flow/Fin: | Cash: | ||||
| Cash Flow/Inv: | |||||
| Business Description |
| The company is engaged in the research and development of products that offer less invasive and painless alternatives to blood tests currently used for glucose monitoring, diabetes screening and infant jaundice. The company's goal is to introduce products that reduce or eliminate pain, are convenient to use and provide rapid results at the point of care, thereby improving patient well being and reducing health care costs. The company's glucose monitoring, diabetes screening and infant jaundice products are based on proprietary electro-optical and microporation technology that can eliminate the pain and inconvenience of a blood sample. The company has entered into collaborative arrangements with Abbott Laboratories, Boehringer Mannheim Corporation and Healthdyne Technologies, Inc. to facilitate the development, commercialization and introduction of its glucose monitoring, diabetes screening and infant jaundice products, respectively. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used for continued development, testing and clinical trials for the company's products; continued research and development; sales marketing and manufacturing activities; capital expenditures; and working capital and other general corporate purposes. |